{"id":"intravenous-clarithromycin","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Nausea and vomiting"},{"rate":"3-8%","effect":"Diarrhea"},{"rate":"2-5%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Phlebitis at injection site"},{"rate":"1-2%","effect":"Headache"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL2109039","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clarithromycin binds irreversibly to the bacterial 50S ribosomal subunit, blocking peptide translocation and inhibiting protein synthesis. This bacteriostatic action prevents bacterial growth and replication. The intravenous formulation allows systemic delivery for serious infections where oral administration is not feasible.","oneSentence":"Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:44.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious respiratory tract infections (pneumonia, bronchitis)"},{"name":"Mycobacterial infections (MAC prophylaxis/treatment)"},{"name":"Other serious bacterial infections requiring intravenous therapy"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07341100","phase":"PHASE2","title":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2026-01","conditions":"Ovarian Epithelial Cancer","enrollment":20},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT04310930","phase":"PHASE2, PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":"Pulmonary Disease Due to Mycobacteria (Diagnosis)","enrollment":300},{"nctId":"NCT07107477","phase":"PHASE3","title":"TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden","status":"RECRUITING","sponsor":"The Central and Eastern European Gynecologic Oncology Group","startDate":"2025-05-01","conditions":"Preterm Premature Rupture of Membranes (PPROM)","enrollment":138},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT04921436","phase":"NA","title":"Modulation of Microbiota Metabolism in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2021-10-03","conditions":"Multiple Organ Dysfunction","enrollment":60},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT03345992","phase":"PHASE3","title":"Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2017-12-15","conditions":"Sepsis, Pneumonia, Gram-Negative Bacteria Infection","enrollment":110},{"nctId":"NCT03043989","phase":"PHASE1","title":"Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-03-21","conditions":"Prostate Cancer","enrollment":4},{"nctId":"NCT03362281","phase":"PHASE3","title":"Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2014-10","conditions":"Peptic Ulcer Hemorrhage","enrollment":540},{"nctId":"NCT03011463","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1","status":"COMPLETED","sponsor":"Dr. R. Pfleger Chemische Fabrik GmbH","startDate":"2016-11","conditions":"Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation","enrollment":24},{"nctId":"NCT00621504","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-01","conditions":"Bacterial Pneumonia","enrollment":606},{"nctId":"NCT01207739","phase":"PHASE4","title":"Persistent Lyme Empiric Antibiotic Study Europe","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2010-09","conditions":"Lyme Disease, Borrelia Infection","enrollment":280},{"nctId":"NCT02343289","phase":"PHASE1","title":"A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-01","conditions":"Healthy","enrollment":18},{"nctId":"NCT01401179","phase":"PHASE3","title":"Antibiotics Study in Preterm Premature Rupture of the Membranes","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2005-04","conditions":"Preterm Premature Rupture of the Membranes","enrollment":101},{"nctId":"NCT01223690","phase":"PHASE3","title":"Clarithromycin as Immunomodulator for the Management of Sepsis","status":"COMPLETED","sponsor":"University of Athens","startDate":"2007-07","conditions":"Sepsis, Severe Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT01326611","phase":"PHASE4","title":"Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants","status":"COMPLETED","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","startDate":"2008-05","conditions":"Chronic Lung Disease","enrollment":273},{"nctId":"NCT00297674","phase":"PHASE4","title":"Intravenous Clarithromycin in Septic Syndrome","status":"COMPLETED","sponsor":"University of Athens","startDate":"2004-06","conditions":"Sepsis, Ventilator Associated Pneumonia","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intravenous Clarithromycin","genericName":"Intravenous Clarithromycin","companyName":"University of Athens","companyId":"university-of-athens","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clarithromycin is an intravenous antibiotic used to treat conditions such as pneumonia, sepsis, and infections caused by Gram-negative bacteria. It is also being studied in clinical trials for its potential to modulate microbiota metabolism in cardiac surgery patients at high risk of postoperative multiple organ dysfunctions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}